Clinical Trial

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase 1/2, open label study of D-1553 in combination with IN10018 to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-05-13; most recent amendment 2026-07-16.
Status change: Recruiting → Active, Not Recruiting 2025-04-06
Status change: Not Yet Recruiting → Recruiting 2023-10-17
Trial Details
NCT Number NCT05379946
Lead Sponsor InventisBio Co., Ltd
Collaborators: InxMed (Shanghai) Co., Ltd.
Conditions Solid Tumor
Enrollment 92 participants
Start Date 2022-10-12
Primary Completion 2027-12-31 (estimated)
Study Completion 2029-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-17